2014
DOI: 10.1038/nrurol.2014.340
|View full text |Cite
|
Sign up to set email alerts
|

Ureteral stent-associated complications—where we are and where we are going

Abstract: Ureteral stents are one of the most commonly used devices in the treatment of benign and malignant urological diseases. However, they are associated with common complications including encrustation, infection, pain and discomfort caused by ureteral tissue irritation and possibly irregular peristalsis. In addition, stent migration and failure due to external compression by malignancies or restenosis occur, albeit less frequently. As these complications restrict optimal stent function, including maintenance of a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
128
0
3

Year Published

2016
2016
2023
2023

Publication Types

Select...
6
3

Relationship

1
8

Authors

Journals

citations
Cited by 161 publications
(139 citation statements)
references
References 81 publications
0
128
0
3
Order By: Relevance
“…13 Meanwhile, degradable stents and novel stent coatings have also been investigated as a strategy to prevent bacterial adherence and subsequent encrustation. 14,15 …”
Section: Discussionmentioning
confidence: 99%
“…13 Meanwhile, degradable stents and novel stent coatings have also been investigated as a strategy to prevent bacterial adherence and subsequent encrustation. 14,15 …”
Section: Discussionmentioning
confidence: 99%
“…Ureteral stents are an integral part of the treatment of different urological conditions such as nephrolithiasis, ureteral stricture, malignant obstruction, ureteral injury and healing [1, 2]. Retained ureteral stents (RUS) may cause infection, encrustation, and patient discomfort.…”
Section: Introductionmentioning
confidence: 99%
“…However, it is associated with patient discomfort and a negative effect on quality of life (QoL) [4][5][6]. To decrease stent-related discomfort, several trials have been conducted to study the effect of pharmacological agents (Alpha-receptor blockers, M-receptor blockers, Chinese herb) and new stent materials on stent-related symptoms [7][8][9]. A reliable and valid measure of such patient experience is therefore becoming a more important assessment of clinical outcomes and would form the basis for the research and development of better treatment methods.…”
mentioning
confidence: 99%